NEWS AND EVENTS
KEEP IN TOUCH WITH US
20 Oct
2018

The First Influenza Drug against Nucleoprotein is About to Enter the Clinical Stage

(Chinese version only)

<Shenzhen Evening News>

對抗流感、子宮內膜異位癥和超級細菌未來將或有新的辦法。10 月 18 日,在知臨集團主辦的香港醫療保健與經濟氣候研討會上,知臨集團發布了當前三個先導項目,包括診斷或者治療流感(ASL-1)、耐甲氧西林金黃色葡萄球菌(ALS-4)、子宮內膜異位癥(NSL-1)。這三個先導項目即將進入臨床階段。

據了解,我國作為癌癥高發區,醫療市場規模逐年遞增,現已成為全球增速最快的生物科技市場。生物醫療科技行業作為一個高風險,高回報的行業,也受到政府的重點關註和大力支持。與此同時,香港作為生物科技投資中心,坐擁近 300 家生物科技相關公司,無論是科研環境或是人才資源都堪稱世界一流。香港科技園已經為新興生物醫療科技公司建立了生物醫療科技支援中心和醫療保健設備研發中心,同時也提供了大量的先進設備支持以助力新興生物醫療科技公司的發展。

據知臨集團創辦人、行政總裁兼執行董事禤駿遠介紹,知臨集團當前三個先導項目包括:診斷或者治療流感(ASL-1)、耐甲氧西林金黃色葡萄球菌(ALS-4)、子宮內膜異位癥(NSL-1)。其中 ASL-1 是一種用於治療甲型流感病毒引起的病毒性感染的小分子藥物,是首創針對核蛋白的新型抗流感候選藥物,與所有目前市場上存在耐藥性問題的抗甲型流感病毒藥物區別開來;而 ALS-4 首創 " 免疫療法 ",通過加強免疫系統對金黃葡萄球菌 ( MRSA ) 的清除功能,防止 MRSA 避過人體免疫系統的防禦侵害人體,是該領域的一項極具突破性的發現。集團的第三個重點項目 NSL-1 是一種用於治療子宮內膜異位癥衍生物。該藥物相比於其他藥物的成效更高、更能夠完全消除子宮內膜異位癥病變。集團的三個先導項目當前均即將進入臨床階段,市場規模有望在 2025 年累計突破 70 億美元。

據了解,知臨集團是一家以香港為基地、處於臨床前階段的醫藥研發企業,知臨集團一直致力於推進一系列嶄新醫療及診斷科技的研發和商品化,以應對未被滿足的醫療需求。同時,還可因地制宜與國家食品藥品監督管理總局(CFDA)認可的臨床研究機構合作,包括香港中文大學、香港大學及香港眼科醫院,以開展臨床試驗。

18 Oct
2018
02 Oct
2018

"Passing Barriers + "Me First"" should be the Attitude of Investors

(Chinese version only)

<Hong Kong Economic Times>

生物科技可說是「燒錢」非常,因研發成本高、回報期長,製作新藥亦面臨相當高的失敗率。

有專業投資者形容,投資生物醫學科技需要有「過關」及「Me First」心態。

為解決生物科技初企及公司融資難的問題,港交所(00388)今年開始,容許未有盈利的生物科技公司於香港上市集資;而政府創科創投基金的5名共同投資夥伴中,百奧財富專門投資成長階段的國際性生命科學公司,如生物製藥及醫療科技等,亦為生物科技公司打開融資新渠道。

不過,港交所行政總裁李小加曾經指出,國際市場上,涉足生物科技公司的投資者多是擁有較高分析能力和抗風險能力的機構投資者,直言並不適合中小散戶。

研發漫長 惟首創產品價值大

知臨集團創辦人兼行政總裁禤駿遠認為,要壯大生物科技之創投生態,投資者必須改變思維,形容要有「過關心態」,因由實驗室研發,到臨床第一期、第二期、第三期測試,每關都可以很漫長,但每過一關,「投資回報就可升幾倍」。

他又認為,投資生物科技要有「Me First」的想法,因首創的產品價值最大,「若只是改變現有藥物的包裝或服用形式,其實沒甚麼意思。」

報道系列 : 創科機遇系列(生物科技)

×
×
×
×
Terms of Use

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.